Results 41 to 50 of about 8,771 (219)

Budget impact analysis of upadacitinib for the management of moderate-to-severe atopic dermatitis in patients treated with systemic therapies in the United States [PDF]

, 2022
Objective: This study evaluated the budget impact of introducing upadacitinib for patients with uncontrolled moderate-to-severe atopic dermatitis (AD) from a United States (U.S.) private payer perspective.
Alobaid, Haya O
core   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Efficacy of upadacitinib has been assessed in trials including Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and Heads Up (NCT03738397).
April W. Armstrong, H. Chih-Ho Hong, Brian M. Calimlim, Marric G. Buessing, Marjorie M. Crowell, Jonathan I. Silverberg   +5 more
doaj   +1 more source

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study

RMD Open
Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined with elsubrutinib (a Bruton’s tyrosine kinase inhibitor ...
Joan T Merrill, Yoshiya Tanaka, Amit Saxena, Xiaofeng Zeng, Martin Aringer, David D’Cruz, Kristin M D’Silva, Ling Cheng, Thao T Doan, Karim R Masri   +9 more
doaj   +1 more source

Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis [PDF]

BackgroundThe oral anti-janus kinase 1 inhibitor upadacitinib has shown a good efficacy-safety profile in the treatment of moderate-to-severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so ...
Batalla, Ana, Botella‐estrada, Rafael, Carretero Hernández, Gregorio, Figueras‐nart, Ignasi, Flórez, Angeles, Martorell‐calatayud, Antonio, Miquel‐miquel, Javier, Sanz‐motilva, Virginia, Suh‐oh, Hae Jin   +8 more
core   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Uncovering the Therapeutic Target and Molecular Mechanism of Upadacitinib on Sjogren’s Syndrome

Biomedical Engineering and Computational Biology
Objective: Upadacitinib, a selective Janus associated kinase 1 (JAK-1) inhibitor, can be prescribed particularly for the clinical treatment with Crohn’s disease or rheumatoid arthritis.
Youguo Yang, Yuan Liu, Xiaofen Li, Yongping Zeng, Weiqian He, Juan Zhou   +5 more
doaj   +1 more source

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

RMD Open
Objective To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.Methods Patients refractory to ≥1 biological disease-modifying ...
Roy Fleischmann, Stephen Hall, Bernard Combe, Andrea Rubbert-Roth, Christina Charles-Schoeman, Nasser Khan, Heidi S Camp, Sebastian Meerwein, Kyle M Carter   +8 more
doaj   +1 more source

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Drugs in Context, 2020
Background: In the randomized, phase III, global SELECTCOMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which ...
Karel Pavelka, Zoltán Szekanecz, Nemanja Damjanov, Branimir Anić, Matija Tomšič, Vadim Mazurov, Marija Maksimovic, Orsolya Nagy, Jerzy Świerkot, Tzvetanka Petranova, Tiina Veldi, Asta Baranauskaitė, Catalin Codreanu, Daina Andersone, Roy Fleischmann   +14 more
doaj   +1 more source

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib

Frontiers in Pharmacology, 2023
Objective: To mine the adverse drug event (ADE) signals of upadacitinib based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to provide a reference for the safe clinical use of the drug.Methods: The ADE data for
Yan Wu, Meihao Wei, Jing Zhang
doaj   +1 more source